Vivos Therapeutics Partners with SoundHealth to Expand Access to Sleep and Allergy Technologies

Reuters02-05

<a href="https://laohu8.com/S/VVOS">Vivos Therapeutics</a> Partners with SoundHealth to Expand Access to Sleep and Allergy Technologies

Vivos Therapeutics Inc., a leader in medical devices and healthcare services for breathing-related sleep disorders, has announced a collaboration with SoundHealth, a Silicon Valley health technology company specializing in AI-enabled allergy and sleep therapeutics. The partnership aims to expand access to SoundHealth’s FDA-cleared airway and sleep health technologies through Vivos’ extensive provider network. As part of the agreement, Vivos will act as a reseller of SoundHealth products, including the Sonu smartphone app, which uses voice biomarkers and facial scanning to monitor airway health. The collaboration leverages SoundHealth’s large craniofacial dataset and innovative technology to promote airway health awareness and improve non-invasive treatment options for sleep and allergy patients.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vivos Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9649526-en) on February 05, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2609530597?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-05 21:45","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2609530597","market":"nz","top_or_hot":-1,"title":"Vivos Therapeutics Partners with SoundHealth to Expand Access to Sleep and Allergy Technologies","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/VVOS\">Vivos Therapeutics</a> Partners with SoundHealth to Expand Access to Sleep and Allergy Technologies\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Vivos <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc., a leader in medical devices and healthcare services for breathing-related sleep disorders, has announced a collaboration with SoundHealth, a Silicon Valley health technology company specializing in AI-enabled allergy and sleep therapeutics. The partnership aims to expand access to SoundHealth’s FDA-cleared airway and sleep health technologies through Vivos’ extensive provider network. As part of the agreement, Vivos will act as a reseller of SoundHealth products, including the Sonu smartphone app, which uses voice biomarkers and facial scanning to monitor airway health. The collaboration leverages SoundHealth’s large craniofacial dataset and innovative technology to promote airway health awareness and improve non-invasive treatment options for sleep and allergy patients.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vivos Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9649526-en) on February 05, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vivos Therapeutics Partners with SoundHealth to Expand Access to Sleep and Allergy Technologies</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVivos Therapeutics Partners with SoundHealth to Expand Access to Sleep and Allergy Technologies\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-02-05 21:45</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/VVOS\">Vivos Therapeutics</a> Partners with SoundHealth to Expand Access to Sleep and Allergy Technologies\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Vivos <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc., a leader in medical devices and healthcare services for breathing-related sleep disorders, has announced a collaboration with SoundHealth, a Silicon Valley health technology company specializing in AI-enabled allergy and sleep therapeutics. The partnership aims to expand access to SoundHealth’s FDA-cleared airway and sleep health technologies through Vivos’ extensive provider network. As part of the agreement, Vivos will act as a reseller of SoundHealth products, including the Sonu smartphone app, which uses voice biomarkers and facial scanning to monitor airway health. The collaboration leverages SoundHealth’s large craniofacial dataset and innovative technology to promote airway health awareness and improve non-invasive treatment options for sleep and allergy patients.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vivos Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9649526-en) on February 05, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0029864427.USD","symbol_name":"TEMPLETON GLOBAL \"A\" (USD) INC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260205:nNDL970l1T:1","article_id":"2609530597","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2609530597","pubTimestamp":1770299111,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Vivos Therapeutics Inc., a leader in medical devices and healthcare services for breathing-related sleep disorders, has announced a collaboration with SoundHealth, a Silicon Valley health technology company specializing in AI-enabled allergy and sleep therapeutics. The partnership aims to expand access to SoundHealth’s FDA-cleared airway and sleep health technologies through Vivos’ extensive provider network. As part of the agreement, Vivos will act as a reseller of SoundHealth products, including the Sonu smartphone app, which uses voice biomarkers and facial scanning to monitor airway health. The collaboration leverages SoundHealth’s large craniofacial dataset and innovative technology to promote airway health awareness and improve non-invasive treatment options for sleep and allergy patients.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0029864427.USD":"TEMPLETON GLOBAL \"A\" (USD) INC","LU0882574055.USD":"富达全球健康医疗A ACC","LU0980610538.SGD":"Natixis Harris Associates US Equity RA SGD-H","IE00B775SV38.USD":"NEUBERGER BERMAN US MULTICAP OPPORTUNITIES \"A\" (USD) ACC","LU1261432733.SGD":"Fidelity World A-ACC-SGD","NDAQ":"纳斯达克OMX交易所","LU0648001328.SGD":"Natixis Harris Associates US Equity RA SGD","LU1150488135.SGD":"First Eagle Amundi Income Builder AHS-MD SGD-H","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","LU0128525929.USD":"TEMPLETON GLOBAL \"A\" (USD) ACC","LU0985489474.SGD":"First Eagle Amundi International AHS-C SGD-H","BK4504":"桥水持仓","LU0187121727.USD":"FIDELITY SUSTAINABLE US EQUITY \"A\" (USD) INC","LU0211327993.USD":"TEMPLETON GLOBAL EQUITY INCOME \"A\" (USD) ACC","LU2244417387.USD":"FIDELITY SUSTAINABLE US EQUITY \"A\" (USD) ACC","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","LU0878866978.SGD":"First Eagle Amundi International AHS-QD SGD-H","BK4588":"碎股","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","LU1489326972.SGD":"First Eagle Amundi International AHS-MD SGD-H","HCA":"HCA控股","BK4112":"金融交易所和数据","LU0310800379.SGD":"FTIF - Templeton Global A Acc SGD","LU0203345920.USD":"SCHRODER ISF QEP GLB ACT. VL \"A\" (USD) ACC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","SG9999014039.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) INC","LU1267930573.SGD":"TEMPLETON GLOBAL \"AA\" (SGD) ACC A","VVOS":"Vivos Therapeutics","BK4185":"保健护理机构","SG9999014005.SGD":"United Global Durable Equities Fund Acc SGD","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","SG9999014021.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) ACC","BK4196":"保健护理服务","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","SG9999014013.SGD":"United Global Durable Equities Fund Dis SGD","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","LU0310799852.SGD":"FTIF - Templeton Global Equity Income A MDIS SGD","LU1119994496.HKD":"FIDELITY WORLD \"A\" (HKD) ACC","LU0068578508.USD":"First Eagle Amundi International Cl AU-C USD","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","LU0130102774.USD":"Natixis Harris Associates US Equity RA USD","LU1267930490.SGD":"TEMPLETON GLOBAL EQUITY INCOME \"AS\" (SGD) INC A","LU1150488218.USD":"First Eagle Amundi Income Builder AU2-MD USD","BK4585":"ETF&股票定投概念","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","LU0203347892.USD":"SCHRODER ISF QEP GLOBAL ACTIVE VALLUE \"A\" (USD)  INC AV","LU1084165304.USD":"FIDELITY WORLD \"A\" (USD) ACC","LU0211328371.USD":"TEMPLETON GLOBAL EQUITY INCOME \"A\" (MDIS) (USD)   INC"},"translate_title":"Vivos Therapeutics与SoundHealth合作扩大睡眠和过敏技术的使用范围","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VVOS":0.9,"HCA":0.9,"NDAQ":0.9},"content_text":"Vivos Therapeutics Partners with SoundHealth to Expand Access to Sleep and Allergy Technologies\n    \n\n        Vivos Therapeutics Inc., a leader in medical devices and healthcare services for breathing-related sleep disorders, has announced a collaboration with SoundHealth, a Silicon Valley health technology company specializing in AI-enabled allergy and sleep therapeutics. The partnership aims to expand access to SoundHealth’s FDA-cleared airway and sleep health technologies through Vivos’ extensive provider network. As part of the agreement, Vivos will act as a reseller of SoundHealth products, including the Sonu smartphone app, which uses voice biomarkers and facial scanning to monitor airway health. The collaboration leverages SoundHealth’s large craniofacial dataset and innovative technology to promote airway health awareness and improve non-invasive treatment options for sleep and allergy patients.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vivos Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9649526-en) on February 05, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2609530597","isCrawlerRequest":true}